Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshihiko Doi

Showing results (81-90 of 247) with videos related to

Pageof 25
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 16, 2016
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patientsAkihito Kawazoe, Takeshi Kuwata, Yasutoshi Kuboki, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancerToshihiko Doi, Kei Muro, Takayuki Yoshino, et al.
International Journal of Clinical Oncology|August 26, 2009
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumorsToshihiko Doi, Atsushi Ohtsu, Makoto Tahara, et al.
Cancer Chemotherapy and Pharmacology|August 20, 2009
Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylateAkira Sawaki, Yasuhide Yamada, Yoshito Komatsu, et al.
Japanese Journal of Clinical Oncology|December 21, 2010
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancerToshihiko Doi, Makoto Tahara, Takayuki Yoshino, et al.
Molecular Cancer Therapeutics|August 10, 2019
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal CancerShigehiro Koganemaru, Yasutoshi Kuboki, Yoshikatsu Koga, et al.
BMC Cancer|February 2, 2018
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascitesHiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, et al.
Clinical Colorectal Cancer|January 3, 2016
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single InstitutionDaisuke Kotani, Kohei Shitara, Akihito Kawazoe, et al.
Anti-Cancer Drugs|August 20, 2015
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumorsToshihiko Doi, Takayuki Yoshino, Kohei Shitara, et al.
Cancer Research and Treatment|May 12, 2017
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 StudyYung-Jue Bang, Toshimi Takano, Chia-Chi Lin, et al.
Pageof 25

Showing results (81-90 of 247) with videos related to

Sort By:
Pageof 25
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 16, 2016
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patientsAkihito Kawazoe, Takeshi Kuwata, Yasutoshi Kuboki, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancerToshihiko Doi, Kei Muro, Takayuki Yoshino, et al.
International Journal of Clinical Oncology|August 26, 2009
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumorsToshihiko Doi, Atsushi Ohtsu, Makoto Tahara, et al.
Cancer Chemotherapy and Pharmacology|August 20, 2009
Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylateAkira Sawaki, Yasuhide Yamada, Yoshito Komatsu, et al.
Japanese Journal of Clinical Oncology|December 21, 2010
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancerToshihiko Doi, Makoto Tahara, Takayuki Yoshino, et al.
Molecular Cancer Therapeutics|August 10, 2019
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal CancerShigehiro Koganemaru, Yasutoshi Kuboki, Yoshikatsu Koga, et al.
BMC Cancer|February 2, 2018
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascitesHiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, et al.
Clinical Colorectal Cancer|January 3, 2016
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single InstitutionDaisuke Kotani, Kohei Shitara, Akihito Kawazoe, et al.
Anti-Cancer Drugs|August 20, 2015
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumorsToshihiko Doi, Takayuki Yoshino, Kohei Shitara, et al.
Cancer Research and Treatment|May 12, 2017
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 StudyYung-Jue Bang, Toshimi Takano, Chia-Chi Lin, et al.
Pageof 25